You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 10,112,942

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,112,942 protect, and when does it expire?

Patent 10,112,942 protects RETEVMO and is included in two NDAs.

This patent has ninety-seven patent family members in forty countries.

Summary for Patent: 10,112,942

Title:	Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Abstract:	Provided herein are compounds of the Formula I: ##STR00001## and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X.sup.1, X.sup.2, X.sup.3, X.sup.4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Inventor(s):	Andrews; Steven W. (Boulder, CO), Aronow; Sean (Boulder, CO), Blake; James F. (Boulder, CO), Brandhuber; Barbara J. (Boulder, CO), Cook; Adam (Boulder, CO), Haas; Julia (Boulder, CO), Jiang; Yutong (Boulder, CO), Kolakowski; Gabrielle R. (Boulder, CO), McFaddin; Elizabeth A. (Boulder, CO), McKenney; Megan L. (Boulder, CO), McNulty; Oren T. (Boulder, CO), Metcalf; Andrew T. (Boulder, CO), Moreno; David A. (Boulder, CO), Tang; Tony P. (Boulder, CO), Ren; Li (Boulder, CO)
Assignee:	Array BioPharma Inc. (Boulder, CO)
Application Number:	15/858,240
Patent Claim Types: see list of patent claims	Composition; Compound;

Drugs Protected by US Patent 10,112,942

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-001	May 8, 2020		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	CAPSULE;ORAL	213246-002	May 8, 2020		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	TABLET;ORAL	218160-001	Apr 10, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	TABLET;ORAL	218160-002	Apr 10, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	TABLET;ORAL	218160-003	Apr 10, 2024		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
Loxo Oncol Eli Lilly	RETEVMO	selpercatinib	TABLET;ORAL	218160-004	Apr 10, 2024		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,112,942

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	109919	⤷ Sign Up
Argentina	109920	⤷ Sign Up
Australia	2017342022	⤷ Sign Up
Australia	2017342027	⤷ Sign Up
Brazil	112019007143	⤷ Sign Up
Brazil	112019007144	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.